Document Detail

Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity.
MedLine Citation:
PMID:  12704403     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To determine the effect of orlistat on weight reduction and the long-term maintenance of this weight loss when associated with a continuous mildly reduced energy diet.
DESIGN: A multicenter, 18-month, double-blind study conducted in 81 hospital centers. Patients were randomized to orlistat 120 mg or placebo three times daily in conjunction with a mildly reduced-energy diet maintained throughout the study.
SUBJECTS: In total, 696 otherwise healthy, overweight patients aged 18-65 y (BMI >or=28 kg/m(2)) were randomized to treatment with orlistat (n=346) or placebo (n=350).
MEASUREMENTS: Body weight, anthropometry, lipid and glycemic control parameters and blood pressure.
RESULTS: After 18 months, patients treated with orlistat lost significantly more body weight compared with placebo (-6.5+/-0.8 vs -3.0+/-0.8%; P=0.0005). After 12 months, 32.9% of orlistat vs 24.5% of placebo patients lost >or=10% of their initial weight (P=0.04). A significantly greater number of patients receiving orlistat treatment maintained this >or=10% weight loss compared to those receiving placebo (28.1 vs 13.8%; P<0.0001). Compared with placebo, orlistat was associated with a greater decrease in fasting blood glucose (-0.86+/-0.12 vs -0.29+/-0.18 mmol/l; P<0.05) and LDL-cholesterol (-13.0+/-1.3 vs -7.0+/-1.3%; P<0.001).
CONCLUSION: A clinically meaningful reduction in body weight and the maintenance of this weight loss is achievable with orlistat treatment and dietary restriction over a period of 18 months. This weight loss resulted in an improvement in risk factors for coronary heart disease.
M Krempf; J-P Louvet; H Allanic; T Miloradovich; J-M Joubert; J-R Attali
Related Documents :
6331623 - Severe peripheral neuropathy following gastric bypass surgery for morbid obesity.
6462993 - Gastric emptying after surgery for the dumping syndrome.
24553523 - Temporal trends of postinjury multiple-organ failure: still resource intensive, morbid,...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity     Volume:  27     ISSN:  -     ISO Abbreviation:  Int. J. Obes. Relat. Metab. Disord.     Publication Date:  2003 May 
Date Detail:
Created Date:  2003-04-21     Completed Date:  2003-05-19     Revised Date:  2014-06-03    
Medline Journal Info:
Nlm Unique ID:  9313169     Medline TA:  Int J Obes Relat Metab Disord     Country:  England    
Other Details:
Languages:  eng     Pagination:  591-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Obesity Agents / adverse effects,  therapeutic use*
Double-Blind Method
Energy Intake
Gastrointestinal Diseases / chemically induced
Lactones / adverse effects,  therapeutic use*
Long-Term Care
Middle Aged
Obesity / drug therapy*
Risk Factors
Treatment Outcome
Weight Loss
Reg. No./Substance:
0/Anti-Obesity Agents; 0/Lactones; 96829-58-2/orlistat

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of a high-protein, energy-restricted diet on weight loss and energy expenditure after weight ...
Next Document:  Physical activity levels in children and adolescents.